Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity.
Douglas RS, Couch S, Wester ST, Fowler BT, Liu CY, Subramanian PS, Tang R, Nguyen QT, Maamari RN, Ugradar S, Hsu K, Karon M, Stan MN.
Douglas RS, et al. Among authors: fowler bt.
J Clin Endocrinol Metab. 2023 Dec 21;109(1):25-35. doi: 10.1210/clinem/dgad637.
J Clin Endocrinol Metab. 2023.
PMID: 37925673
Free PMC article.
Clinical Trial.